Skip to content

Efficacy of Adding Magnesium Sulfate in Periarticular Injection for Pain Management in Patients Undergoing Partial Hip Replacement for Femoral Neck Fracture: A Double-Blinded, Randomized Controlled Trial

Efficacy of Adding Magnesium Sulfate in Periarticular Injection for Pain Management in Patients Undergoing Partial Hip Replacement for Femoral Neck Fracture: A Double-Blinded, Randomized Controlled Trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20250103002
Enrollment
100
Registered
2025-01-03
Start date
2025-04-02
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Femoral neck fracture Hip fracture in elderly Femoral neck fracture Hip fracture in elderly Partial hip replacement Periarticular injection Magnesium sulfate

Interventions

50% MgSO4, 2 mL (Atlantic Laboratory Corporation Ltd., Thailand) 0.5% Bupivacaine, 40 mL (Aspen, Australia) Ketorolac, 30 mg (Siu Guan Chemical Industrial, Chai Yi, Taiwan) (1 mL) Epinephrine, 1 mg (T
Experimental Drug,No Intervention Drug
M-PAI,C-PAI

Sponsors

Navamindradhiraj University Research Fund
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged between 60 and 90 years., 2. Diagnosed with intracapsular neck of femur fracture and underwent bipolar partial hip replacement surgery., 3. Classified as ASA physical status class I-III in terms of physical risk assessment.

Exclusion criteria

Exclusion criteria: 1. Patients who are bedridden or unable to walk before surgery., 2. Patients with morbid obesity, defined as a BMI greater than 40 kg/m2., 3. Patients with a history of allergy to any ingredients in the periarticular injection solution, including Ketorolac, Bupivacaine, and Epinephrine., 4. Patients with a history of using analgesic drugs specified in the study., 5. Patients with a history of opioid use or chronic pain within 3 months before surgery., 6. Patients with neurological diseases affecting walking, such as hemiplegia, paralysis, or muscle weakness., 7. Patients with renal failure or impaired kidney function, defined as a glomerular filtration rate (GFR) less than 30 mL/min/1.73m2.

Design outcomes

Primary

MeasureTime frame
Numeric Pain Scale q4h until 48 hours, 72 h Postoperative pain score

Secondary

MeasureTime frame
Opioid use 24, 48 and 72 hours Postoperative Morphine use,Side effect from opioid 24, 48 and 72 hours Incidence of side effect from opioid,Functional Hip Score 2, 6, 12 weeks Harris Hip Score,Complications IPD, 2, 6, 12 weeks Complication from surgery

Countries

Thailand

Contacts

Public ContactIttiwat Onklin

Faculty of Medicine, Vajira Hospital, Navamindradhiraj University

ittiwat@nmu.ac.th022443376

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026